✦ LIBER ✦

In recurrent epithelial ovarian carcinoma during the drug shortage era

✍ Scribed by Berger, J.; Smith, A.; Zorn, K.; Sukumvanich, P.; Olawaiye, A.; Edwards, R.; Kelley, J.; Krivak, T.

Book ID: 122359510
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 59 KB
Volume: 131
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2013.07.058

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of secondary cytoreductive surg

The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

✍ Scott M. Eisenkop; Richard L. Friedman; Nick M. Spirtos 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 2 views

BACKGROUND. This study examined the impact of secondary cytoreductive surgery on survival of patients with recurrent epithelial ovarian carcinoma. ## METHODS. One hundred six patients with a disease free interval (DFI) Ͼ 6 months after primary treatment underwent secondary cytoreductive surgery. M

Expression of Twist increases the risk f

Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients

✍ Hosono, S; Kajiyama, H; Terauchi, M; Shibata, K; Ino, K; Nawa, A; Kikkawa, F 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 351 KB

A phase 2 study of the cytotoxic immunoc

A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma

✍ Stephen Y. Chan; Alan N. Gordon; Robert E. Coleman; James B. Hall; Mark S. Berge 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 183 KB

Phase II evaluation of dasatinib in the

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 205 KB

A phase II study of ramucirumab (IMC-112

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

✍ Penson, Richard T.; Moore, Kathleen M.; Fleming, Gini F.; Braly, Patricia; Schim 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 637 KB

A phase II study of vorinostat in the tr

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Susan C. Modesitt; Michael Sill; James S. Hoffman; David P. Bender 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 251 KB